Lyell

Lyell Immunopharma is a fully integrated biopharmaceutical company based in South San Francisco, California, with approximately 201 employees. The company is focused on developing next-generation T-cell reprogramming technologies to create transformative cell therapies for cancer patients, particularly targeting hematologic malignancies and solid tumors.